Comparison of efficacy and safety between loading-dose atorvastatin and rosuvastatin in cerebral infarction

Comparison of efficacy and safety between loading-dose atorvastatin and rosuvastatin in cerebral infarction

To analyze the efficacy and safety of loading-dose atorvastatin and rosuvastatin in the treatment of cerebral infarction (CI). A total of 151 CI patients treated at the Third Affiliated Hospital of Qiqihar Medical University from January 2015 to February 2020 retrospectively were selected and divide...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of translational research 2024-01, Vol.16 (9), p.4633-4642
Hauptverfasser: Li, Yanchao, Zhang, Di, Liu, Shuang, Ni, Weihui, Wang, Chunying, Yu, Bolin, Guan, Jing, Shao, Jun, Zhang, Qi
Format: Artikel
Sprache:eng
Schlagworte:
Original
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 4642
container_issue 9
container_start_page 4633
container_title American journal of translational research
container_volume 16
creator Li, Yanchao
Zhang, Di
Liu, Shuang
Ni, Weihui
Wang, Chunying
Yu, Bolin
Guan, Jing
Shao, Jun
Zhang, Qi
description To analyze the efficacy and safety of loading-dose atorvastatin and rosuvastatin in the treatment of cerebral infarction (CI). A total of 151 CI patients treated at the Third Affiliated Hospital of Qiqihar Medical University from January 2015 to February 2020 retrospectively were selected and divided into four groups: conventional atorvastatin, loading-dose atorvastatin, conventional rosuvastatin, and loading-dose rosuvastatin. Primary outcomes assessed included changes in National Institutes of Health Stroke Scale (NIHSS) scores, clinical efficacy, alterations in serum lipid indices, liver function, inflammation markers, CI indices, and the incidence of adverse reactions. After treatment, all groups showed a significant decrease in NIHSS scores (all P
doi_str_mv 10.62347/GQIE8716
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11470334</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3116337736</sourcerecordid><originalsourceid>FETCH-LOGICAL-c231t-d30d9632edee0a1e5ab5ed8310d3f44d44d065ec59d573f3438569c336d981ee3</originalsourceid><addsrcrecordid>eNpVkUFLAzEQhYMoWqsH_4DsUQ-rm85udvckUmotFETQc0iTSY1uk5qklf57Q6tFYSDD5OPNSx4hF7S4YQMo69vx82TU1JQdkB5tS8gbWtLDP_0JOQ3hvShY1bLBMTmBFtqmKuse-Ri6xVJ4E5zNnM5QayOF3GTCqiwIjXGTzTB-Idqsc0IZO8-VC5iJ6PxahCiisVvYu7DaD1JJ9Djzoku9Fl5G4-wZOdKiC3j-c_bJ68PoZfiYT5_Gk-H9NJcDoDFXUKiWwQAVYiEoVmJWoWqAFgp0WapU6SEoq1ZVNWgooalYKwGYahuKCH1yt9NdrmYLVBJtTEb40puF8BvuhOH_b6x543O35pSWdQFJsE-ufhS8-1xhiHxhgsSuExbdKnCglAHUNbCEXu9QmX4geNT7PbTg23T4bzqJvfxrbE_-xgHfo5uNZw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3116337736</pqid></control><display><type>article</type><title>Comparison of efficacy and safety between loading-dose atorvastatin and rosuvastatin in cerebral infarction</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Li, Yanchao ; Zhang, Di ; Liu, Shuang ; Ni, Weihui ; Wang, Chunying ; Yu, Bolin ; Guan, Jing ; Shao, Jun ; Zhang, Qi</creator><creatorcontrib>Li, Yanchao ; Zhang, Di ; Liu, Shuang ; Ni, Weihui ; Wang, Chunying ; Yu, Bolin ; Guan, Jing ; Shao, Jun ; Zhang, Qi</creatorcontrib><description>To analyze the efficacy and safety of loading-dose atorvastatin and rosuvastatin in the treatment of cerebral infarction (CI). A total of 151 CI patients treated at the Third Affiliated Hospital of Qiqihar Medical University from January 2015 to February 2020 retrospectively were selected and divided into four groups: conventional atorvastatin, loading-dose atorvastatin, conventional rosuvastatin, and loading-dose rosuvastatin. Primary outcomes assessed included changes in National Institutes of Health Stroke Scale (NIHSS) scores, clinical efficacy, alterations in serum lipid indices, liver function, inflammation markers, CI indices, and the incidence of adverse reactions. After treatment, all groups showed a significant decrease in NIHSS scores (all P&lt;0.0001). The loading-dose groups exhibited greater reductions in NIHSS scores compared to the conventional groups (both P&lt;0.0001). No significant difference was found in NIHSS scores between the two loading-dose groups (P&gt;0.05). The loading-dose groups demonstrated higher efficacy than the conventional groups (both P&lt;0.05), with no significant difference between the two loading-dose groups (both P&gt;0.05). Loading-dose rosuvastatin showed superior improvement in blood lipid control compared to loading-dose atorvastatin (P&lt;0.05). There were no significant differences in liver function indices among the groups (all P&gt;0.05). Inflammation and myocardial indices intensified 24 hours after treatment, with milder intensification in the loading-dose rosuvastatin group compared to the loading-dose atorvastatin group (P&lt;0.05). The incidences of adverse reactions did not significantly differ among the groups (all P&gt;0.05). Both loading-dose atorvastatin and rosuvastatin demonstrated increased clinical efficacy in the treatment of CI patients, ensuring safety and effectiveness. However, rosuvastatin exhibited superior efficacy in blood lipid control. These findings provide valuable guidance for the clinical management of CI.</description><identifier>ISSN: 1943-8141</identifier><identifier>EISSN: 1943-8141</identifier><identifier>DOI: 10.62347/GQIE8716</identifier><identifier>PMID: 39398547</identifier><language>eng</language><publisher>United States: e-Century Publishing Corporation</publisher><subject>Original</subject><ispartof>American journal of translational research, 2024-01, Vol.16 (9), p.4633-4642</ispartof><rights>AJTR Copyright © 2024.</rights><rights>AJTR Copyright © 2024 2024</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c231t-d30d9632edee0a1e5ab5ed8310d3f44d44d065ec59d573f3438569c336d981ee3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11470334/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11470334/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39398547$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Li, Yanchao</creatorcontrib><creatorcontrib>Zhang, Di</creatorcontrib><creatorcontrib>Liu, Shuang</creatorcontrib><creatorcontrib>Ni, Weihui</creatorcontrib><creatorcontrib>Wang, Chunying</creatorcontrib><creatorcontrib>Yu, Bolin</creatorcontrib><creatorcontrib>Guan, Jing</creatorcontrib><creatorcontrib>Shao, Jun</creatorcontrib><creatorcontrib>Zhang, Qi</creatorcontrib><title>Comparison of efficacy and safety between loading-dose atorvastatin and rosuvastatin in cerebral infarction</title><title>American journal of translational research</title><addtitle>Am J Transl Res</addtitle><description>To analyze the efficacy and safety of loading-dose atorvastatin and rosuvastatin in the treatment of cerebral infarction (CI). A total of 151 CI patients treated at the Third Affiliated Hospital of Qiqihar Medical University from January 2015 to February 2020 retrospectively were selected and divided into four groups: conventional atorvastatin, loading-dose atorvastatin, conventional rosuvastatin, and loading-dose rosuvastatin. Primary outcomes assessed included changes in National Institutes of Health Stroke Scale (NIHSS) scores, clinical efficacy, alterations in serum lipid indices, liver function, inflammation markers, CI indices, and the incidence of adverse reactions. After treatment, all groups showed a significant decrease in NIHSS scores (all P&lt;0.0001). The loading-dose groups exhibited greater reductions in NIHSS scores compared to the conventional groups (both P&lt;0.0001). No significant difference was found in NIHSS scores between the two loading-dose groups (P&gt;0.05). The loading-dose groups demonstrated higher efficacy than the conventional groups (both P&lt;0.05), with no significant difference between the two loading-dose groups (both P&gt;0.05). Loading-dose rosuvastatin showed superior improvement in blood lipid control compared to loading-dose atorvastatin (P&lt;0.05). There were no significant differences in liver function indices among the groups (all P&gt;0.05). Inflammation and myocardial indices intensified 24 hours after treatment, with milder intensification in the loading-dose rosuvastatin group compared to the loading-dose atorvastatin group (P&lt;0.05). The incidences of adverse reactions did not significantly differ among the groups (all P&gt;0.05). Both loading-dose atorvastatin and rosuvastatin demonstrated increased clinical efficacy in the treatment of CI patients, ensuring safety and effectiveness. However, rosuvastatin exhibited superior efficacy in blood lipid control. These findings provide valuable guidance for the clinical management of CI.</description><subject>Original</subject><issn>1943-8141</issn><issn>1943-8141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNpVkUFLAzEQhYMoWqsH_4DsUQ-rm85udvckUmotFETQc0iTSY1uk5qklf57Q6tFYSDD5OPNSx4hF7S4YQMo69vx82TU1JQdkB5tS8gbWtLDP_0JOQ3hvShY1bLBMTmBFtqmKuse-Ri6xVJ4E5zNnM5QayOF3GTCqiwIjXGTzTB-Idqsc0IZO8-VC5iJ6PxahCiisVvYu7DaD1JJ9Djzoku9Fl5G4-wZOdKiC3j-c_bJ68PoZfiYT5_Gk-H9NJcDoDFXUKiWwQAVYiEoVmJWoWqAFgp0WapU6SEoq1ZVNWgooalYKwGYahuKCH1yt9NdrmYLVBJtTEb40puF8BvuhOH_b6x543O35pSWdQFJsE-ufhS8-1xhiHxhgsSuExbdKnCglAHUNbCEXu9QmX4geNT7PbTg23T4bzqJvfxrbE_-xgHfo5uNZw</recordid><startdate>20240101</startdate><enddate>20240101</enddate><creator>Li, Yanchao</creator><creator>Zhang, Di</creator><creator>Liu, Shuang</creator><creator>Ni, Weihui</creator><creator>Wang, Chunying</creator><creator>Yu, Bolin</creator><creator>Guan, Jing</creator><creator>Shao, Jun</creator><creator>Zhang, Qi</creator><general>e-Century Publishing Corporation</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20240101</creationdate><title>Comparison of efficacy and safety between loading-dose atorvastatin and rosuvastatin in cerebral infarction</title><author>Li, Yanchao ; Zhang, Di ; Liu, Shuang ; Ni, Weihui ; Wang, Chunying ; Yu, Bolin ; Guan, Jing ; Shao, Jun ; Zhang, Qi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c231t-d30d9632edee0a1e5ab5ed8310d3f44d44d065ec59d573f3438569c336d981ee3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Original</topic><toplevel>online_resources</toplevel><creatorcontrib>Li, Yanchao</creatorcontrib><creatorcontrib>Zhang, Di</creatorcontrib><creatorcontrib>Liu, Shuang</creatorcontrib><creatorcontrib>Ni, Weihui</creatorcontrib><creatorcontrib>Wang, Chunying</creatorcontrib><creatorcontrib>Yu, Bolin</creatorcontrib><creatorcontrib>Guan, Jing</creatorcontrib><creatorcontrib>Shao, Jun</creatorcontrib><creatorcontrib>Zhang, Qi</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>American journal of translational research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Li, Yanchao</au><au>Zhang, Di</au><au>Liu, Shuang</au><au>Ni, Weihui</au><au>Wang, Chunying</au><au>Yu, Bolin</au><au>Guan, Jing</au><au>Shao, Jun</au><au>Zhang, Qi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of efficacy and safety between loading-dose atorvastatin and rosuvastatin in cerebral infarction</atitle><jtitle>American journal of translational research</jtitle><addtitle>Am J Transl Res</addtitle><date>2024-01-01</date><risdate>2024</risdate><volume>16</volume><issue>9</issue><spage>4633</spage><epage>4642</epage><pages>4633-4642</pages><issn>1943-8141</issn><eissn>1943-8141</eissn><abstract>To analyze the efficacy and safety of loading-dose atorvastatin and rosuvastatin in the treatment of cerebral infarction (CI). A total of 151 CI patients treated at the Third Affiliated Hospital of Qiqihar Medical University from January 2015 to February 2020 retrospectively were selected and divided into four groups: conventional atorvastatin, loading-dose atorvastatin, conventional rosuvastatin, and loading-dose rosuvastatin. Primary outcomes assessed included changes in National Institutes of Health Stroke Scale (NIHSS) scores, clinical efficacy, alterations in serum lipid indices, liver function, inflammation markers, CI indices, and the incidence of adverse reactions. After treatment, all groups showed a significant decrease in NIHSS scores (all P&lt;0.0001). The loading-dose groups exhibited greater reductions in NIHSS scores compared to the conventional groups (both P&lt;0.0001). No significant difference was found in NIHSS scores between the two loading-dose groups (P&gt;0.05). The loading-dose groups demonstrated higher efficacy than the conventional groups (both P&lt;0.05), with no significant difference between the two loading-dose groups (both P&gt;0.05). Loading-dose rosuvastatin showed superior improvement in blood lipid control compared to loading-dose atorvastatin (P&lt;0.05). There were no significant differences in liver function indices among the groups (all P&gt;0.05). Inflammation and myocardial indices intensified 24 hours after treatment, with milder intensification in the loading-dose rosuvastatin group compared to the loading-dose atorvastatin group (P&lt;0.05). The incidences of adverse reactions did not significantly differ among the groups (all P&gt;0.05). Both loading-dose atorvastatin and rosuvastatin demonstrated increased clinical efficacy in the treatment of CI patients, ensuring safety and effectiveness. However, rosuvastatin exhibited superior efficacy in blood lipid control. These findings provide valuable guidance for the clinical management of CI.</abstract><cop>United States</cop><pub>e-Century Publishing Corporation</pub><pmid>39398547</pmid><doi>10.62347/GQIE8716</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1943-8141
ispartof American journal of translational research, 2024-01, Vol.16 (9), p.4633-4642
issn 1943-8141
1943-8141
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11470334
source EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Original
title Comparison of efficacy and safety between loading-dose atorvastatin and rosuvastatin in cerebral infarction
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T11%3A48%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20efficacy%20and%20safety%20between%20loading-dose%20atorvastatin%20and%20rosuvastatin%20in%20cerebral%20infarction&rft.jtitle=American%20journal%20of%20translational%20research&rft.au=Li,%20Yanchao&rft.date=2024-01-01&rft.volume=16&rft.issue=9&rft.spage=4633&rft.epage=4642&rft.pages=4633-4642&rft.issn=1943-8141&rft.eissn=1943-8141&rft_id=info:doi/10.62347/GQIE8716&rft_dat=%3Cproquest_pubme%3E3116337736%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3116337736&rft_id=info:pmid/39398547&rfr_iscdi=true